CVKD Stock — Cadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics, Inc. Common Stock (CVKD)

Updated October 16, 2026.

CVKD is a Stock. Total return is -98.2% over the past 3.7 years, 200.3 points behind SPY at 102.1%.

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing novel therapies for immune and thrombotic conditions, with lead candidate Tecarfarin (an oral anticoagulant in Phase 3 trials), CAD-1005 (a first-in-class treatment for heparin-induced thrombocytopenia that completed Phase 2), and Frunexian (a factor XIa inhibitor in Phase 1). The company does not currently distribute dividends. This security appeals to investors seeking exposure to clinical-stage biotech development with potential for significant value creation upon positive trial results or regulatory milestones.

CVKD performance versus SPY

Price and return data through 2026-10-16.

Total return is -98.2% over the past 3.7 years, 200.3 points behind SPY at 102.1%. Over the past year its total return — price change plus distributions reinvested — is -92.1%. Its deepest 1-year drawdown was 93.8%.

CVKD key facts

Asset type

Stock

Asset class

Equity

Inception date

01/20/2023

Distribution frequency

None

Last close

$1.09 (as of 2026-10-16)

Market cap

$3,888,675

Average volume

169777.0

Beta

1.95

Payout ratio

0.0%

EPS

$-4.91

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CVKD risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 93.8%.

Who may consider CVKD — and who may not

It is a weaker fit for investors who need monthly cash flow (CVKD does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CVKD

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions